Patients taking vancomycin often need careful monitoring to avoid kidney damage and ensure the drug works. This large review looked at 63 studies to see if a pharmacist helping with the process made a difference. The answer was a clear yes. When pharmacists managed the drug levels, patients had fewer cases of acute kidney injury. This serious side effect happens when the kidneys get hurt by the medicine. The review found that pharmacist involvement reduced this risk significantly compared to when no pharmacist was involved. The team also saw better success rates for the treatment overall. Patients were more likely to reach the right blood levels of the drug when a pharmacist guided the process. This meant the medicine worked better for more people. The studies also showed that doctors adjusted dosages more often when a pharmacist was on the team. These changes helped keep patients safe and healthy during their treatment. While the review did not report on hospital stay length or medication duration, the safety and effectiveness gains are important. The findings suggest that having a pharmacist involved in managing vancomycin is a smart move for patient care.
Meta-analysis shows pharmacist interventions improve vancomycin TDM outcomes and reduce kidney injury riskPharmacist oversight improves vancomycin safety and success rates in patients
AI-generated summary of the cited source, checked by automated accuracy review. How we work
This meta-analysis examined the impact of pharmacist interventions compared to non-pharmacist intervention groups in patients receiving vancomycin under therapeutic drug monitoring. The review synthesized data from 63 studies to evaluate various clinical and operational outcomes. The authors assessed the incidence of acute kidney injury, clinical effective rate, mortality, and several metrics related to therapeutic drug monitoring processes.
Key findings demonstrate that pharmacist interventions were associated with a reduced risk of acute kidney injury, with a relative risk of 0.67 (95% CI = 0.57, 0.78, P < 0.05). Additionally, the incidence of acute kidney injury defined by a serum creatinine increase of ≥0.5 mg/dL or ≥50% from baseline was reduced with a relative risk of 0.58 (95% CI = 0.45, 0.74, P < 0.05). The clinical effective rate improved with a relative risk of 1.11 (95% CI = 1.06, 1.17, P < 0.05), and 30-day mortality was reduced with a relative risk of 0.52 (95% CI = 0.33, 0.82, P < 0.05).
Operational metrics also improved significantly. The correct blood sampling time rate increased with a relative risk of 1.52 (95% CI = 1.25, 1.83, P < 0.05), and the target blood concentration attainment rate increased with a relative risk of 1.60 (95% CI = 1.49, 1.72, P < 0.05). The proportion of dosage regimen adjustments based on TDM results increased substantially with a relative risk of 2.68 (95% CI = 1.93, 3.70, P < 0.05). Outcomes such as duration of medication, length of hospital stay, and TDM timeliness showed no significant effect. Safety data regarding adverse events were not reported in the source material.